Organogenesis (NASDAQ:ORGO) Shares Up 4.3% – Still a Buy?

Organogenesis (NASDAQ:ORGO)’s share price traded up 4.3% during trading on Thursday . The company traded as high as $2.45 and last traded at $2.44. 681,845 shares were traded during trading, a decline of 16% from the average session volume of 814,458 shares. The stock had previously closed at $2.34.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ORGO. BTIG Research cut Organogenesis from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. UBS Group set a $3.00 target price on Organogenesis in a research report on Thursday, May 28th. Truist Financial began coverage on Organogenesis in a research note on Thursday, May 28th. They set a “hold” rating and a $3.00 target price on the stock. Wall Street Zen downgraded shares of Organogenesis from a “buy” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings lowered shares of Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Organogenesis presently has a consensus rating of “Hold” and an average target price of $5.75.

Organogenesis Price Performance

The company has a current ratio of 3.53, a quick ratio of 3.16 and a debt-to-equity ratio of 0.05. The business’s fifty day moving average is $2.46 and its 200 day moving average is $3.36. The company has a market cap of $313.98 million, a P/E ratio of -12.84 and a beta of 1.32.

Organogenesis (NASDAQ:ORGO) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.08). Organogenesis had a negative net margin of 0.84% and a positive return on equity of 9.63%. The firm had revenue of $37.23 million for the quarter, compared to the consensus estimate of $43.26 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Strs Ohio bought a new stake in Organogenesis in the 1st quarter valued at about $105,000. Creative Planning lifted its holdings in Organogenesis by 84.5% during the second quarter. Creative Planning now owns 35,392 shares of the company’s stock valued at $130,000 after purchasing an additional 16,205 shares during the last quarter. Cetera Investment Advisers purchased a new stake in Organogenesis during the second quarter valued at about $222,000. American Century Companies Inc. boosted its position in Organogenesis by 25.6% during the second quarter. American Century Companies Inc. now owns 164,793 shares of the company’s stock worth $603,000 after purchasing an additional 33,573 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in Organogenesis by 36.6% during the second quarter. Russell Investments Group Ltd. now owns 168,152 shares of the company’s stock worth $617,000 after purchasing an additional 45,021 shares during the period. Institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.